AI-designed drugs hit roughly 90% Phase I success
Nearly double the historical average, with discovery-to-clinic timelines compressed.
Nearly double the historical average, with discovery-to-clinic timelines compressed.
Risk 0 · Mitigation 3.
Nearly double the historical average, with discovery-to-clinic timelines compressed.
Nearly double the historical average, with discovery-to-clinic timelines compressed.
Risk 0 · Mitigation 3.